Patient and disease characteristics (N = 142)

	Number	Percent
Age at start of anti-PD-1/PD-L1 therapy
< 60	58	40.8
≥ 60	84	59.2
Smoker
No	69	48.6
Yes	72	50.7
Unknown	1	0.7
Gender
Female	41	28.9
Male	101	71.1
Histology
Clear cell RCC	120	84.5
Non-clear cell RCC	22	15.5
Presence of Sarcomatoid
No	119	83.8
Yes	22	15.5
Unknown	1	0.7
Presence of Rhabdoid
No	134	94.4
Yes	6	4.2
Unknown	2	1.4
IMDC risk group at start of anti-PD-1/PD-L1 therapy
Favorable	26	18.3
Intermediate	85	59.9
Poor	31	21.8
Line of therapy
1	62	43.7
2	37	26.1
≥ 3	43	30.3
Type of anti-PD-1/PD-L1 therapy
Monotherapy	76	53.5
Combination therapy PD-L1 + VEGF targeted therapy (n = 46) PD-1 + VEGF-targeted therapy (n = 9) PD-1 + CTLA-4 (n = 7) PD-1 + other (n = 4)	66	46.5
	Median	range
NLR - baseline	3.9	1.3–42.4
NLR - week 6	4.1	1.1–96.4